DVAX Dynavax Technologies Corp

Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray, Chief Executive Officer, will present at the 39th Annual Cowen Healthcare Conference on Wednesday, March 13, at 8:40 a.m. ET.

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.dynavax.com/events-presentations.

About Dynavax Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.

ContactHeather Rowe Vice President, Investor Relations & Corporate Communications 510-665-7269